857070-67-8

Basic information

• Product Name: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol
• Synonyms: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol;[2-(3-morpholin-4-ylpropylamino)-3H-benzimidazol-5-yl]methanol
• CAS NO: 857070-67-8
• Molecular Formula: C15H22N4O2
• Molecular Weight: 290.36078
• Mol File: 857070-67-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol(857070-67-8)
• EPA Substance Registry System: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol(857070-67-8)

Safety Data

• Hazardous Substances Data: 857070-67-8(Hazardous Substances Data)

Usage

General Description

(2-((3-Morpholinopropyl)amino)-1H-benzo[d]imidazol-6-yl)methanol is a chemical compound with potential pharmaceutical applications. It is a benzimidazole derivative that contains a morpholinopropylamine group and a methanol moiety. Its structure indicates that it could have an affinity for both adrenergic and serotonergic receptors in the central nervous system, making it a potential candidate for the treatment of psychiatric and neurological disorders. Further research and testing are needed to fully understand its pharmacological properties and potential therapeutic uses.

Upstream product

• 123-00-2 4-(3-Aminopropyl)morpholine 
• 857035-29-1 2-chloro-3H-benzoimidazole-5-carboxylic acid ethyl ester 
• 857070-66-7 (2-chloro-3H-benzoimidazol-5-yl)methanol 
• 634602-84-9 2-hydroxy-3H-benzoimidazole-5-carboxylic acid ethyl ester 
• 37466-90-3 ethyl 3,4-diaminobenzoate 

Downstream Products

• 857067-39-1 2-[5-hydroxymethyl-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl]-6-methylpyridin-3-ol 
• 857067-38-0 2-[6-hydroxymethyl-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl]-6-methylpyridin-3-ol 
• 857070-65-6 3-(3-hydroxy-6-methylpyridin-2-ylmethyl)-2-(3-morpholin-4-ylpropylamino)-3H-benzoimidazole-5-carbaldehyde 

Relevant articles and documents

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.

MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereoc